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Introduction {#sec005}
============

Intra-abdominal infections (IAIs) represent a vast variety of diseases, including infections of single organs (e.g. cholecystitis, appendicitis, diverticulitis, cholangitis, pancreatitis, and salpingitis), peritonitis, and intra-abdominal abscesses \[[@pone.0193977.ref001],[@pone.0193977.ref002]\]. Inpatients with IAIs often possess infections that are dangerous, abnormal, and accompanied by significant mortality; complicated IAIs are associated with 10.5% of mortality worldwide \[[@pone.0193977.ref003]\].

Patients with both complicated and uncomplicated IAIs may be commonly treated with antimicrobial therapy \[[@pone.0193977.ref004]\]. Inappropriate antimicrobial therapy may give rise to poor patient outcomes, such as higher mortality, longer hospitalization, and increased economic burden. Furthermore, there is an increased risk that future antimicrobial therapy will be less effective for both previous and new inpatients, because of antimicrobial resistance (AMR) \[[@pone.0193977.ref001]\].

AMR occurs when medications used to cure infections become ineffective \[[@pone.0193977.ref005]\]. AMR includes multiple drug resistance (MDR), resistance to three or more types of antimicrobial agents and non-MDR, and resistance to less than three types of antimicrobial agents \[[@pone.0193977.ref006]\]. Inappropriate antimicrobial usage is widespread and contributes to the rapid spread of AMR pathogens, particularly in developing countries \[[@pone.0193977.ref007]\]. It is widely accepted that there is a direct association between antimicrobial usage and the development of AMR, which poses significant risks to human health. In 2014, the World Health Organization (WHO) announced the coming of a post-antibiotic era, in which common infections and minor injuries that had been treatable for decades can once again spread and kill \[[@pone.0193977.ref008]\]. It was estimated that 10 million deaths each year would occur worldwide, with one million deaths occurring in China in 2050. Additionally, the global costs were estimated to be \$100 trillion USD, with costs to China accounting for \$20 trillion USD \[[@pone.0193977.ref009]\].

Recently, AMR is becoming more complicated and MDR pathogens are increasingly serious. There is a dramatically increasing trend in the incidence of IAIs caused by MDR pathogens, which creates a major challenge in the treatment of IAIs \[[@pone.0193977.ref010]\]. In the past few decades, a growing number of MDR pathogens have been detected from IAIs, including methicillin-resistant *Staphylococcus aureus* (MRSA), carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), extended-spectrum *β-lactamase* (ESBL)-producing *Escherichia coli* or *Klebsiella pneumoniae*, carbapenem-resistant *Enterobacteriaceae* (CRE) and carbapenem-resistant *Acinetobacter baumannii* (CRAB) \[[@pone.0193977.ref011]\]. In addition, MDR IAIs further increase medical costs, stemming from the prolonged length of stay (LOS) in hospitals and poor patient outcomes because of antimicrobial treatment failures \[[@pone.0193977.ref012]\].

Many studies have investigated the cost analysis of antimicrobial therapy for treatment of IAIs \[[@pone.0193977.ref013],[@pone.0193977.ref014],[@pone.0193977.ref015],[@pone.0193977.ref016]\]. Studies on clinical characteristics and pathogen distribution of IAIs have also been conducted \[[@pone.0193977.ref017],[@pone.0193977.ref018]\]. However, very few studies have examined the association between MDR and total medical costs (TMCs) among patients with IAIs \[[@pone.0193977.ref019]\]. Compared to previous studies, the present study takes both AMR and TMCs into consideration, focusing on the impact of MDR on TMCs. This study, conducted at a teaching hospital located in the Zhejiang province of China, aims to compare the TMCs among patients with IAIs between MDR and non-MDR groups, and to estimate the additional costs at a national level in China.

Methods {#sec006}
=======

Study site {#sec007}
----------

This study was conducted in a tertiary teaching and general hospital in Hangzhou, Zhejiang Province, China, which has a total of 3200 beds and approximately 121,900 discharged patients each year. We specifically chose this hospital as our study site because it is in the provincial capital city, which is the political and cultural center of Zhejiang province. In addition, a high quality hospital information system (HIS) is existent, which makes the collection of complete and reliable data possible.

Study design, sample, and sampling {#sec008}
----------------------------------

This is a retrospective study. Patients with IAIs and AMR pathogens were included in our analysis, and were divided into MDR and non-MDR groups based on antimicrobial susceptibility testing.

Firstly, we randomly selected a sample of 40% of all inpatients discharged between 2014 and 2015 in the hospital, due to limiting budget and the large number of patients. Then, two researchers independently manually collected disease diagnosis. Subsequently, we screened in 254 patients according to the International Classification of Disease, 10^th^ revision (ICD-10) codes for IAIs and 230 patients were truly patients with IAIs by systematic manual review of electronic medical records. Moreover, we identified antimicrobial resistant pathogens based on antimicrobial susceptibility testing. Eventually, 101 patients with IAIs were included (64 MDR patients and 37 non-MDR patients) after excluding those without laboratory test results, as well as those without any pathogens detected and those without antimicrobial resistant pathogens based on the hypothesis and the objective in the analysis ([Fig 1](#pone.0193977.g001){ref-type="fig"}).

![Sample collection procedure.](pone.0193977.g001){#pone.0193977.g001}

In the sampling, we used the following procedures. Firstly, the identification numbers of all discharged patients were collected from the HIS and serial numbers corresponding to the identification numbers were generated in Excel 2013. Then, random-between (bottom, top) command was applied to randomly select the patients. If one patient has multiple visits, we regarded this patient as multiple unique patients.

Data collection {#sec009}
---------------

Demographic and clinical parameters influencing medical costs were collected from electronic medical records. Any disagreements were resolved with consultation from an experienced physician.

The demographic parameters included identification number, age, sex, medical insurance, and health outcome. Clinical parameters included discharge department, disease diagnosis, susceptibility testing results, antimicrobial usage, surgery, LOS, and ICU admission. Based on the existing parameters, we determined more parameters that may influence medical costs, as follows: combination antimicrobial therapy, carbapenem usage, number of administered antimicrobial agents, and number of pathogens.

The TMC for each patient's entire admission was calculated. TMC includes ward stays, ICU stays, laboratory tests, medical tests, microbiological cultures, surgical procedures, antimicrobial therapy and other drugs during the period of hospital stay \[[@pone.0193977.ref020]\]. Since the study was conducted over a span of 2 years, we adjusted TMCs to the year 2015's currency using the Consumer Price Index for China \[[@pone.0193977.ref020]\]. The study was approved by the institutional review board of Zhejiang University School of Public Health, and owing to the retrospective nature of the study, informed consent was not deemed necessary. All patient data were anonymized prior to analysis.

Data analysis {#sec010}
-------------

Statistical analyses were performed with the SPSS 17.0 for Windows. The Chi-square test or Fisher exact test was used to analyze categorical parameters. The Student *t-*test was conducted for analyzing age, while a Mann-Whitney *U* test was used for analyzing other parameters of non-normal distribution. Then, the effect of each parameter on the TMCs was evaluated by univariate analysis and a Kruskal-Wallis nonparametric test was employed to assess categorical parameters on TMCs, because it was confirmed to be non-normally distributed. In order to control the effects of parameters on TMCs, a generalized linear model was performed, which included the following parameters: outcome, insurance, age, sex, surgery, combination antimicrobial therapy, carbapenem usage, LOS, ICU admission, number of administered antimicrobial agents, and number of pathogens. Finally, all tests were two-tailed and *P* values less than 0.05 were considered as statistically significant. To correct for the non-normal distribution of the TMCs, a logarithmic transformation was specified.

The parameters in the generalized linear model were selected due to our hypothesis and previous research \[[@pone.0193977.ref017],[@pone.0193977.ref019],[@pone.0193977.ref021]\]. We assumed that TMCs are associated with demographic parameters such as age, sex, insurance, outcome, and clinical parameters such as surgery, combination antimicrobial therapy, carbapenem usage, LOS, ICU admission, number of administered antimicrobial agents, and number of pathogens. Moreover, clinical parameters positively influenced TMCs.

Results {#sec011}
=======

Sample characteristics {#sec012}
----------------------

A total of 101 patients with IAIs caused by AMR pathogens were included, 63.4% of which were MDR patients. The average age of all patients was 57.2 years and most of the patients were men. About half of the patients were covered by insurance, received combination antimicrobial therapy, or admitted to the ICU. Most of them had been previously treated with carbapenems and had undergone surgery. The main outcome (67.3%) upon hospital discharge was an improvement in health ([Table 1](#pone.0193977.t001){ref-type="table"}).

10.1371/journal.pone.0193977.t001

###### Characteristics among patients with intra-abdominal infections.

![](pone.0193977.t001){#pone.0193977.t001g}

  Parameters                                    Total(n = 101)   MDR(n = 64)   Non-MDR(n = 37)   P-value
  --------------------------------------------- ---------------- ------------- ----------------- ----------------------------------------------
  Age, mean±SD, years                           57.2(20.4)       58.4(20.1)    55.1(20.9)        0.434
  Male, (%)                                     72.3             70.3          75.7              0.562
  Insurance, (%)                                58.4             50            73                0.024[\*](#t001fn001){ref-type="table-fn"}
  Outcome, (%)                                                                                   0.675
  Cure                                          14.9             12.5          18.9              
  Improvement                                   67.3             68.8          64.9              
  Else                                          17.8             18.8          16.2              
  Number of administered antimicrobial agents   3.4(2.1)         4.02(2.3)     2.4(1.3)          \<0.000[\*](#t001fn001){ref-type="table-fn"}
  Carbapenem usage, (%)                         79.2             82.8          73                0.24
  Combination antimicrobial therapy, (%)        44.6             56.2          24.3              0.002[\*](#t001fn001){ref-type="table-fn"}
  Number of pathogens                           2.4(2.1)         3.0(2.4)      1.4(0.6)          \<0.000[\*](#t001fn001){ref-type="table-fn"}
  Surgery, (%)                                  81.2             84.4          75.7              0.281
  ICU, (%)                                      61.4             76.6          35.1              \<0.000[\*](#t001fn001){ref-type="table-fn"}
  LOS, mean±SDb, days                           25.4(25.3)       31.0(28.8)    15.59(13.1)       \<0.000[\*](#t001fn001){ref-type="table-fn"}

\* Significance was determined at the 0.05 level.

SD: standard deviation; LOS: length of stay; ICU: intensive care unit; MDR: multiple drug resistance

Compared to non-MDR patients, a larger number of administered antimicrobial agents, a larger number of pathogens, and a longer LOS were observed in the MDR patients. Additionally, there were significantly more patients in the MDR group who were covered by insurance, received combination antimicrobial therapy, or admitted to the ICU. However, there were no significant differences between the MDR and non-MDR groups with regard to age, sex, carbapenem usage, surgery, and outcome ([Table 1](#pone.0193977.t001){ref-type="table"}).

Pathogens used for analysis were strains collected in the susceptibility tests, with duplicate isolates (the same pathogen from the same patient) being excluded \[[@pone.0193977.ref018],[@pone.0193977.ref019]\]. A total of 262 pathogens were detected from 101 patients with IAIs. Out of all pathogens, 35 were non-resistant pathogens, 126 were non-MDR pathogens, and 101 were MDR pathogens. CRAB was the most frequently isolated MDR pathogen, followed by MRSA, ESBL-producing pathogen, CRE, methicillin-resistant coagulase negative *Staphylococci* (MRCNS), methicillin-resistant *Staphylococcus epidermis* (MRSE), and CRPA. For MDR pathogens, the most frequently submitted sample type was sputum, followed by pus and drainage fluid. *Escherichia coli* was the most frequently isolated out of the non-MDR pathogens, followed by *Klebsiella pneumoniae*, *Enterococcus faecium*, *Stenotrophomonas maltophilia*, *Acinetobacter baumannii*, *Enterococcus faecalis*, *Morganella morganii*, and other pathogens ([S1 Table](#pone.0193977.s001){ref-type="supplementary-material"}). For non-MDR pathogens, drainage fluid was the most common sample type, followed by sputum, ascites, pus, and other types ([S2 Table](#pone.0193977.s002){ref-type="supplementary-material"}).

Total medical costs {#sec013}
-------------------

Patients with MDR pathogens were associated with a mean TMC of ¥ 90201 higher than that of non-MDR patients. Other parameters with a significant association with TMC were age ≤65 years, age \>65 years, female, male, insurance, combination antimicrobial therapy, treatment with carbapenems, number of administered antimicrobial agents \>3 agents, surgery, LOS \>15 days, and admission to the ICU. There were no significant differences in other parameters on TMCs ([Table 2](#pone.0193977.t002){ref-type="table"}).

10.1371/journal.pone.0193977.t002

###### Total medical costs.

![](pone.0193977.t002){#pone.0193977.t002g}

  Parameters                                    MDR      Non-MDR   P-value           
  --------------------------------------------- -------- --------- --------- ------- ----------------------------------------------
  Total medical costs                           131801   135097    41600     31974   \<0.000[\*](#t002fn002){ref-type="table-fn"}
  Antimicrobial costs                           24914    36409     4734      4417    \<0.000[\*](#t002fn002){ref-type="table-fn"}
  Age                                                                                
  ≤65                                           112508   12268     35050     32789   0.004[\*](#t002fn002){ref-type="table-fn"}
  \>65                                          158249   149229    53693     27608   0.002[\*](#t002fn002){ref-type="table-fn"}
  Sex                                                                                
  Female                                        135130   129703    40841     38302   0.008[\*](#t002fn002){ref-type="table-fn"}
  Male                                          130396   138721    41844     30466   0.001[\*](#t002fn002){ref-type="table-fn"}
  Insurance                                                                          
  No                                            118327   121332    35470     30363   0.006[\*](#t002fn002){ref-type="table-fn"}
  Yes                                           145275   148307    43871     32812   0.001[\*](#t002fn002){ref-type="table-fn"}
  Outcome                                                                            
  Cure                                          74336    58635     23065     16256   0.054
  Improvement                                   129104   140014    46610     35290   0.008[\*](#t002fn002){ref-type="table-fn"}
  Else                                          180001   144025    43184     26655   0.002[\*](#t002fn002){ref-type="table-fn"}
  Number of administered antimicrobial agents                                        
  ≤3                                            59219    59671     38982     33706   0.22
  \>3                                           195844   150662    52821     21488   \<0.000[\*](#t002fn002){ref-type="table-fn"}
  Combination antimicrobial therapy                                                  
  No                                            63742    60214     35686     30805   0.101
  Yes                                           184736   153190    59999     29911   0.001[\*](#t002fn002){ref-type="table-fn"}
  Carbapenem usage                                                                   
  No                                            13024    11575     17695     15149   0.434
  Yes                                           156453   135950    50454     32170   \<0.000[\*](#t002fn002){ref-type="table-fn"}
  Number of pathogens                                                                
  ≤1                                            47105    40948     35249     28144   0.482
  \>1                                           176166   146015    53326     36321   \<0.000[\*](#t002fn002){ref-type="table-fn"}
  Surgery                                                                            
  No                                            41120    63109     26922     19128   0.87
  Yes                                           148594   138491    46318     34056   \<0.000[\*](#t002fn002){ref-type="table-fn"}
  ICU                                                                                
  No                                            22225    25364     28688     19805   0.001[\*](#t002fn002){ref-type="table-fn"}
  Yes                                           165345   137355    65438     36962   \<0.000[\*](#t002fn002){ref-type="table-fn"}
  LOS                                                                                
  1\~                                           39958    42999     33179     22433   0.906
  15\~                                          103428   56477     49172     29606   0.004[\*](#t002fn002){ref-type="table-fn"}
  30\~                                          237570   166241    75090     61950   0.017[\*](#t002fn002){ref-type="table-fn"}

All costs are expressed in 2015 constant Chinese Yuan

\* Significance was determined at the 0.05 level

SD: standard deviation; LOS: length of stay; MDR: multi drug resistance; ICU: intensive care unit

Factors influencing total medical costs {#sec014}
---------------------------------------

In the generalized linear model, in the MDR group, the most significant parameters affecting TMCs for patients with IAIs included admission to the ICU, carbapenem usage, number of pathogens, and LOS. The most influential parameter was admission to the ICU. Moreover, in the non-MDR group, the most significant parameters affecting TMCs for patients with IAIs included carbapenem usage, admission to the ICU, number of administered antimicrobial agents, LOS, and age. Carbapenem usage was the most influential parameter. In the MDR group, we found that TMCs among patients with carbapenem usage, or admission to the ICU were 2.42 times or 2.52 times as high as that among patients without, respectively. TMCs increased by 1.09 times or 1.01 times when the number of pathogens increased by one pathogen or LOS increased by one day, respectively. In the non-MDR group, we found that TMCs among patients with carbapenem usage or admission to the ICU were 1.55 times or 1.50 times of that among patients without, respectively. TMCs increased by 1.17 times, 1.11 times or 1.02 times when the number of administered antimicrobial agents increased by one agent, LOS increased by one day, or the age increased by one year ([Table 3](#pone.0193977.t003){ref-type="table"}).

10.1371/journal.pone.0193977.t003

###### Factors influencing total medical costs.

![](pone.0193977.t003){#pone.0193977.t003g}

  Parameters                                    MDR           Non-MDR                                                                                                                                                                                        
  --------------------------------------------- ------------- --------- ------- ------- ---------------------------------------------- ---------------------------------------------- ------- ------- ------- ---------------------------------------------- ----------------------------------------------
                                                (Intercept)   9.20      0.31    8.58    9.81                                           \<0.000[\*](#t003fn001){ref-type="table-fn"}   7.63    0.34    6.95    8.30                                           \<0.000[\*](#t003fn001){ref-type="table-fn"}
  Sex                                           Male          -0.03     0.14    -0.30   0.25                                           0.859                                          0.27    0.16    -0.04   0.59                                           0.090
  Female                                        0                                                                                      0                                                                                                                     
  Insurance                                     Yes           -0.16     0.13    -0.41   0.09                                           0.215                                          0.03    0.17    -0.31   0.37                                           0.864
  No                                            0                                                                                      0                                                                                                                     
  Outcome                                       Else          -0.19     0.24    -0.67   0.29                                           0.431                                          -0.13   0.26    -0.64   0.38                                           0.616
  Improvement                                   -0.36         0.20      -0.75   0.02    0.066                                          -0.19                                          0.21    -0.60   0.21    0.351                                          
  Cure                                          0                                                                                      0                                                                                                                     
  Combination antimicrobial therapy             Yes           0.22      0.15    -0.08   0.52                                           0.145                                          0.04    0.21    -0.36   0.45                                           0.836
  No                                            0                                                                                      0                                                                                                                     
  Carbapenem usage                              Yes           0.89      0.32    0.26    1.51                                           0.005[\*](#t003fn001){ref-type="table-fn"}     0.44    0.17    0.10    0.77                                           0.011[\*](#t003fn001){ref-type="table-fn"}
  No                                            0                                                                                      0                                                                                                                     
  Surgery                                       Yes           -0.16     0.23    -0.62   0.29                                           0.485                                          0.30    0.18    -0.07   0.66                                           0.109
  No                                            0                                                                                      0                                                                                                                     
  ICU                                           Yes           0.93      0.28    0.39    1.47                                           0.001[\*](#t003fn001){ref-type="table-fn"}     0.40    0.16    0.08    0.72                                           0.013[\*](#t003fn001){ref-type="table-fn"}
  No                                            0                                                                                      0                                                                                                                     
  Age                                           0.00          0.00      0.00    0.01    0.269                                          0.02                                           0.00    0.01    0.03    \<0.000[\*](#t003fn001){ref-type="table-fn"}   
  Number of administered antimicrobial agents   0.04          0.04      -0.03   0.11    0.262                                          0.15                                           0.07    0.02    0.29    0.023[\*](#t003fn001){ref-type="table-fn"}     
  Number of pathogens                           0.08          0.03      0.02    0.15    0.008[\*](#t003fn001){ref-type="table-fn"}     0.14                                           0.12    -0.11   0.38    0.367                                          
  LOS                                           0.01          0.00      0.01    0.02    \<0.000[\*](#t003fn001){ref-type="table-fn"}   0.11                                           0.12    -0.12   0.34    \<0.000[\*](#t003fn001){ref-type="table-fn"}   

\*Significance was determined at the 0.05 level

MDR: multi-drug resistant; SD: standard deviation; CI: confidence interval; ICU: intensive care unit; LOS: length of stay

Total medical costs in whole country {#sec015}
------------------------------------

The mean TMC difference between the MDR and non-MDR groups was ¥ 90201. The rates of MDR IAIs (number of patients with MDR IAIs / number of patients with IAIs) or non-MDR IAIs (number of patients with non-MDR IAIs / number of patients with IAIs) were 27.83% or 16.09%, respectively. Additionally, the rate of IAIs (number of patients with IAIs / number of patients) was 0.587%. In China, there were nearly 1,235,870 cases of IAIs, including 343,943 cases with MDR pathogens and 198,851 cases with non-MDR pathogens \[[@pone.0193977.ref022]\]. If our results are applied to the whole country, the sum of all attributable TMC was ¥ 37 billion. The societal costs, furthermore, were ¥ 111 billion in 2015, based on WHO suggestion that the societal costs may be more than 3 times the direct costs caused by AMR \[[@pone.0193977.ref023]\].

Discussion {#sec016}
==========

Few studies have investigated the impact of MDR on TMCs among patients with IAIs, despite its heavy burden on the Chinese health system. One study focused on the ESBL-producing pathogens but the published data were from 2000 \[[@pone.0193977.ref019]\]. To our knowledge, our study is the first investigation to provide an overall view of the attributable costs of MDR IAIs in China. Moreover, this is one of few real-world data analyses on Chinese patients, especially in the face of the emergence and spread of MDR pathogens in China.

Our study reveals that MDR is an important driver of TMCs, as results show that MDR inpatients with IAIs are associated with larger number of administered antimicrobial agents, larger number of pathogens, and less likely to have insurance, which are the factors contributing mostly to both TMCs and antimicrobial costs. Several systematic reviews suggest that TMCs attributable to MDR pathogens \[[@pone.0193977.ref024]\] and due to IAIs \[[@pone.0193977.ref025],[@pone.0193977.ref026]\] were considerably high. Moreover, Bijie Hu et al. found that IAIs caused by ESBL-positive producing pathogens were significantly associated with longer LOS, higher TMCs and higher antimicrobial costs \[[@pone.0193977.ref019]\].

In generalized linear model, it was also noted that admission to the ICU has a strong positive correlation with TMCs. Indeed, the majority of previous studies have shown that ICU patients are more likely to undergo surgery and receive more kinds of antimicrobial agents \[[@pone.0193977.ref027],[@pone.0193977.ref028]\]. All the above factors could lead to acquiring resistant pathogens. A reduction in admissions to the ICU may improve inpatient safety, in addition to increasing the quality of care and potentially hospital turnover, and reducing economic burden.

It is known that patients with MDR pathogens are associated with longer LOS compared with patients with non-MDR pathogens, which suggests that differences in costs may be related to LOS. Some studies also indicated that even a one day reduction in hospitalization may result in substantial cost-savings \[[@pone.0193977.ref029],[@pone.0193977.ref030]\].

Patients with MDR pathogens were associated with a significant increase in TMCs, because they were treated with carbapenems, admitted to the ICU, stayed longer in hospital, and had more pathogens present. Carbapenems are often considered as drugs of a last resort in strategies for MDR infections, and exposure to carbapenems was associated with carbapenem resistance \[[@pone.0193977.ref031],[@pone.0193977.ref032]\]. Moreover, empirical antimicrobial therapy is essential to improving patient outcomes, but it could potentially lead to unnecessary exposure to broad-spectrum antimicrobial agents \[[@pone.0193977.ref033]\], resulting in MDR and thus increasing TMCs \[[@pone.0193977.ref034]\]. In addition, the emergence of MDR pathogens can also lead to higher frequencies of failure for empirical antimicrobial therapy, resulting in even higher TMCs \[[@pone.0193977.ref034]\].

In China, there is a trend of AMR increasing across multiple antimicrobial agents. Between 2005 and 2014, rates of ESBL-producing *Escherichia coli* were between 51.7% and 55.8%. Carbapenem resistance among *Klebdiella pneumonia* and *Acinetobacter baumannii* increased from 2.4% to 13.4%, and from 31% to 66.7%, respectively \[[@pone.0193977.ref035]\]. In this study, IAIs were mostly caused by *Escherichia coli* and *Klebsiella pneumoniae*, which is consistent with other studies. However, it has been revealed that these pathogens often fail to be treated with various *β-lactam* agents but carbapenems continue to retain activity \[[@pone.0193977.ref036]\]. Moreover, this study has a higher proportion of patients with CRAB, compared to other pathogens, indicating that the efficacy of carbapenems against ESBL-producing pathogens is decreasing and CRAB is becoming an increasingly serious matter \[[@pone.0193977.ref037]\].

Several limitations are worth noting. Firstly, due to the nature of retrospective study, we cannot distinguish colonization or infection, which incur significantly different costs. IAIs, however, unlike bloodstream infection or pneumonia, have less chance of colonization. Secondly, future studies should be carried out to directly estimate the societal costs. In this study, we only estimated direct medical costs, and used the relationship between medical costs and societal costs suggested by WHO to estimate the societal costs. This estimate may overestimate the economic burden and may not apply to the Chinese situation nationally. In addition, since this study was conducted only in one tertiary teaching and general hospital in Zhejiang province, generalization of the direct costs to a national level may be overestimated. Thus, multicenter and prospective studies are needed in the future. Lastly, the Acute Physiology and Chronic Health Evaluation II score is a powerful instrument for stratifying risk that is often used for evaluating the severity of patients \[[@pone.0193977.ref002]\], which was not obtainable in the present HIS.

Conclusions {#sec017}
===========

This retrospective study shows the heavy burden associated with MDR among patients with IAIs. We conservatively estimate that a large amount of medical costs per hospitalization can be saved, if MDR pathogens can be substantially reduced. The enormous economic burden imposed by MDR IAIs should attract the attention of decision makers in various fields. Moreover, our results provide information that should lead to increased efforts to reduce inappropriate antimicrobial therapy in clinical practice, in order to prevent the emergence and spread of MDR pathogens and to further reduce their economic burden.
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